ExactScience vs Neuproscan
Side-by-side comparison · Updated May 2026
| Description | Exact Sciences Corp. is a leading molecular diagnostics company focused on transforming cancer care through prevention, early detection, and treatment guidance. Their cutting-edge product portfolio includes non-invasive screening tests like Cologuard® for colorectal cancer, Oncotype DX® for predicting cancer recurrence, and OncoExTra® for genomic profiling. The company also offers Riskguard™ for hereditary cancer risk assessment and is pioneering multi-cancer early detection tests. Committed to innovation and scientific validation, Exact Sciences plays a pivotal role in cancer diagnostics, earning endorsements from clinical guidelines and continuous certification as a Great Place to Work®. | NeuProScan is a versatile AI platform designed to predict the likelihood of developing Alzheimer's disease years in advance by analyzing a single MRI scan. This tool is beneficial for both individual doctors and large hospitals, as it can be used on-device or in the cloud and supports the creation of custom AI models. The platform stands out for its accuracy and efficiency, selecting only the most impactful MRI slices for analysis, thereby improving diagnostic precision and optimizing costly PET scan utilization. |
| Category | Healthcare | Healthcare |
| Rating | No reviews | No reviews |
| Pricing | Free | Pricing unavailable |
| Starting Price | Free | N/A |
| Plans |
| — |
| Use Cases |
|
|
| Tags | molecular diagnosticscancer carepreventionearly detectiontreatment guidance | AIMedicalAlzheimer'sDiagnosisMRI |
| Features | ||
| Comprehensive suite of cancer tests across the care continuum, including early detection and screening. | ||
| Offers Cologuard®, a non-invasive at-home stool DNA test for colorectal cancer screening. | ||
| Develops blood tests like Oncoguard® Liver for early detection of hepatocellular carcinoma and Riskguard™ for hereditary cancer risk assessment. | ||
| Provides advanced tests still in development, such as Cancerguard™ for multiple cancer detection. | ||
| Treatment guidance through tests like Oncotype DX Breast and Colon Recurrence Scores for assessing cancer recurrence and therapy benefits. | ||
| OncoExTra® test for aiding late-stage cancer therapy selection. | ||
| Supports patient and provider through logins for test ordering and results tracking. | ||
| Backed by extensive scientific research, publications, and clinical studies. | ||
| Engages in community outreach and health equity initiatives. | ||
| AI-driven predictions | ||
| Single MRI scan analysis | ||
| Customizable AI models | ||
| On-device and cloud operations | ||
| Impactful MRI slice selection | ||
| High diagnostic accuracy | ||
| Supports research purposes | ||
| Beneficial for doctors and hospitals | ||
| Optimizes costly PET scans | ||
| User-friendly interface | ||
| View ExactScience | View Neuproscan | |
Modify This Comparison
Also Compare
Explore more head-to-head comparisons with ExactScience and Neuproscan.